Results 51 to 60 of about 784,229 (242)

Methylation biomarkers can distinguish pleural mesothelioma from healthy pleura and other pleural pathologies

Molecular Oncology, EarlyView.
We developed and validated a DNA methylation–based biomarker panel to distinguish pleural mesothelioma from other pleural conditions. Using the IMPRESS technology, we translated this panel into a clinically applicable assay. The resulting two classifier models demonstrated excellent performance, achieving high AUC values and strong diagnostic accuracy.
Janah Vandenhoeck, Nele De Meulenaere, Thomas Vanpoucke, Joe Ibrahim, Dieter Peeters, Suresh Krishan Yogeswaran, Wen Wen, Paul Van Schil, Jeroen M. H. Hendriks, Jo Raskin, Jan van Meerbeeck, Guy Van Camp, Ken Op de Beeck   +12 more
wiley   +1 more source

Panel discussion on the application of MCDA tools

Cost Effectiveness and Resource Allocation, 2018
Prioritization in healthcare is particularly sensitive to subjective biases and data asymmetry. Yet making data-based and objective decisions are critical to optimizing long term individual and societal benefit.
Michael Watson
doaj   +1 more source

Factor associated with willingness to pay for prevention of cancer: a study of prostate cancer screening

Cost Effectiveness and Resource Allocation, 2023
Introduction This study investigates Iranian men’s willingness to pay (WTP) for prostate cancer (PCa) screening and influencing factor, along with the impact of information.
Hiro Farabi, Najmeh Moradi, Aziz Ahmadzadeh, Seyed Mohammad Kazem Agamir, Abdolreza Mohammadi, Aziz Rezapour   +5 more
doaj   +1 more source

Detection of circulating tumor DNA in colorectal cancer patients using a methylation‐specific droplet digital PCR multiplex

Molecular Oncology, EarlyView.
We developed a cost‐effective methylation‐specific droplet digital PCR multiplex assay containing tissue‐conserved and tumor‐specific methylation markers. The assay can detect circulating tumor DNA with high accuracy in patients with localized and metastatic colorectal cancer.
Luisa Matos do Canto, Louise Raunkilde, Jan Lindebjerg, Mads Malik Aagaard, Christina Therkildsen, Jakob Kleif, Lars Henrik Jensen, Torben Frøstrup Hansen, Rikke Fredslund Andersen   +8 more
wiley   +1 more source

Cost-effectiveness of implant movement analysis in aseptic loosening after hip replacement: a health-economic model

Cost Effectiveness and Resource Allocation, 2023
Objective To investigate the cost-effectiveness of using Implant Movement Analysis (IMA) to follow up suspected aseptic loosening when the diagnosis after an initial X-ray is not conclusive, compared with a diagnostic pathway with X-ray follow-up ...
Davide Lovera, Olof Sandberg, Maziar Mohaddes, Hanna Gyllensten   +3 more
doaj   +1 more source

Perspectives in educating molecular pathologists on liquid biopsy: Toward integrative, equitable, and decentralized precision oncology

Molecular Oncology, EarlyView.
Liquid biopsy enables minimally invasive, real‐time molecular profiling through analysis of circulating biomarkers in biological fluids. This Perspective highlights the importance of training pathologists through integrative educational programs, such as the European Masters in Molecular Pathology, to ensure effective and equitable implementation of ...
Marius Ilié, Umberto Malapelle, Catherine Alix‐Panabières, Claus Lindbjerg Andersen, Sandra Chlebowski, Vivien Lake, Caroline Lacoux, Virginie Lespinet‐Fabre, Olivier Bordone, Simon Heeke, Christophe Bontoux, Ellen Heitzer, Klaus Pantel, Paul Hofman   +13 more
wiley   +1 more source

The use of cost-effectiveness analysis for health benefit package design – should countries follow a sectoral, incremental or hybrid approach?

Cost Effectiveness and Resource Allocation, 2023
Background Countries around the world are increasingly rethinking the design of their health benefit package to achieve universal health coverage. Countries can periodically revise their packages on the basis of sectoral cost-effectiveness analyses, i.e.
Rob Baltussen, Gavin Surgey, Anna Vassall, Ole F. Norheim, Kalipso Chalkidou, Sameen Siddiqi, Mojtaba Nouhi, Sitaporn Youngkong, Maarten Jansen, Leon Bijlmakers, Wija Oortwijn   +10 more
doaj   +1 more source

Next‐generation proteomics improves lung cancer risk prediction

Molecular Oncology, EarlyView.
This is one of very few studies that used prediagnostic blood samples from participants of two large population‐based cohorts. We identified, evaluated, and validated an innovative protein marker model that outperformed an established risk prediction model and criteria employed by low‐dose computed tomography in lung cancer screening trials.
Megha Bhardwaj, Clara Frick, Ben Schöttker, Bernd Holleczek, Hermann Brenner   +4 more
wiley   +1 more source

Global bibliometric analysis of cost effectiveness analysis in healthcare research from 2013 to 2023

Cost Effectiveness and Resource Allocation
Background Cost-effectiveness analysis (CEA) has become a crucial technique in appraising the efficiency of healthcare interventions and resource allocation decisions.
Kemdi Lugard Okoroiwu, Henshaw Uchechi Okoroiwu, Love Ogochukwu Ude, Chidimma Odilia Ezuma, Emmanuel Ikechukwu Omeje   +4 more
doaj   +1 more source

Assessing the impact of grief on quality of life, work productivity, and health outcomes for parents bereaved from SMA: A study protocol

Cost Effectiveness and Resource Allocation, 2023
Background U.S. cost-effectiveness recommendations suggest that analyses should include all costs and effects relevant to the decision problem [1]. However, in many diseases, including spinal muscular atrophy (SMA), few studies have evaluated bereaved ...
Abigail G. Riley, Christina M. Mulé, Debra Lerner, Lisa Belter, Colleen McCarthy O’Toole, Stacey Kowal, David Fox, Sheila Shapouri, Tamara Vesel, Tara A. Lavelle   +9 more
doaj   +1 more source